Life Sciences and Pharma IP 2026

JAPAN Law and Practice Contributed by: Hirofumi Tada, Ohno & Partners

Ohno & Partners is one of the leading intellectual property law firms located in Tokyo, with 29 attorneys who are highly specialised in IP litigation and pros ‑ ecution. The firm has worked on many difficult litiga ‑ tions and established numerous precedents before the Supreme Court and the Intellectual Property High Court – representing almost 40% (6 out of 16) of the Intellectual Property High Court en banc cases in Ja ‑

pan, demonstrating a very strong track record. Ohno & Partners has handled many pharmaceutical litiga ‑ tions for both small molecules and biologics, and current Japanese antibody patent practice is largely based on case law established by the team. The firm is committed to offering its clients the highest quality, full-service solutions across all areas of intellectual property rights.

Author

Hirofumi Tada is an exceptionally experienced patent litigator at Ohno & Partners, admitted to practice in both Japan and California. His experience covers more than 150 patent litigations and encompasses the

areas of pharmaceuticals, biotechnology, chemicals, AI, IoT, information technology, and software, among other fields. Having worked in the US at Finnegan, Hirofumi is also very familiar with US patent practices.

Ohno & Partners Marunouchi Kitaguchi Bldg 21F 1-6-5, Marunouchi Chiyoda-ku Tokyo 100-0005 Japan

Tel: +81 3 5218 2331 Fax: +81 3 5218 2332 Email: info@oslaw.org Web: www.oslaw.org

109 CHAMBERS.COM

Powered by